May 1, 2017 / 3:46 PM / 3 months ago

BRIEF-Kitov Pharmaceuticals discloses additional details of Israeli Securities Authority investigation

1 Min Read

May 1 (Reuters) - Kitov Pharmaceuticals Holdings Ltd :

* Investigation by Israeli Securities Authority related to data monitoring committee appointed in relation to KIT-302 phase III trial

* Continuing with process of completing new drug application for KIT-302, which is expected to be submitted to FDA during Q2 2017

* Company appointed independent statistician, orthopedist to serve as DMC to review preliminary results of initial patient group

* ISA investigating circumstances surrounding actual dissemination of statistical analysis to members of DMC - SEC filing

* ISA also investigating if dissemination of statistical analysis led to misleading disclosures in company's public filings - SEC filing

* "This matter had no impact whatsoever on the validity of the statistical analysis of the KIT-302 phase III clinical trial data" Source text - (bit.ly/2pAtpoO) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below